Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat plus azacitidine versus azacitidine in first-line higher-risk MDS, CMML, or low-blast AML
2017-000318-40Phase 3Unknown
- Sponsor
- Millennium Pharmaceuticals
- Start
- Oct 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) comparing Pevonedistat plus azacitidine with Single-agent azacitidine (2 arms). Primary endpoint: Event-free survival. Status: unknown.
02
Drugs
pevonedistatazacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2017-000318-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000318-40.